Physician profile
Even Wang
NPI 1871813691
$35,314.43
in general payments reported to CMS, 2019-2025
40 companies · $1,887 in 2025
The $1,887 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $6,568 · 2021: $21K · 2022: $2,409 · 2023: $1,269 · 2024: $2,180 · 2025: $1,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,335.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23,589.86 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $7,254.47 | 2019-2022 | |
| Lilly USA, LLC | $599.21 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Alexion Pharmaceuticals, INC. | $568.60 | 2020-2025 | Ultomiris |
| Ucb, INC. | $471.50 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Novartis Pharmaceuticals Corporation | $470.19 | 2019-2025 | |
| Eisai INC. | $320.05 | 2023-2025 | |
| Biogen, INC. | $270.24 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Celgene Corporation | $264.76 | 2023-2025 | Zeposia |
| Sk Life Science, INC. | $155.77 | 2024-2025 | |
| Merz North America, INC. | $95.82 | 2022 | |
| Argenx US, INC. | $94.73 | 2024-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $83.81 | 2019-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $77.86 | 2022-2025 | Crexont |
| Tanabe Pharma America, INC. | $70.98 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Even Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.